Class Action launched against Northfield Laboratories

Northfield Laboratories are in the gun with a complaint alleging, among other claims, that on February 22, 2006, a story in The Wall Street Journal reported that the
data available to defendants from the clinical trial but not to the public,
revealed that ten patients who received PolyHeme suffered a heart attack
within seven days, and two of those died. The claim further states that the data showed defendants that none of the patients in the clinical trial who received real blood were
found to have suffered a heart attack. In the aftermath of receiving this
data, defendants shut down the clinical study and kept this adverse data
hidden from investors. On February 22, 2006, Northfield's common stock fell to
$11.64 a share on over 4.1 million shares traded.